Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin versus ketamine in treatment-resistant depression
2018-004480-31Phase 2Active
- Sponsor
- National Institute of Mental Health, Czech Republic
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in treatment-resistant depression (TRD) comparing Psilocybin arm, Ketamine arm and Midazolam arm (3 arms). Started Mar 2019; status: active.
02
Drugs
psilocybinketaminemidazolam
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2018-004480-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004480-31.